Opioid Taper Study
CompletedNCT03912298
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The purpose of this study is to determine the effect of opioid taper on pain sensitivity in patients with chronic pain. In a well-characterized sample of men and women with chronic neuropathic pain on high-dose opioid therapy, experimental pain responses (cold-pressor, quantitative sensory testing) will be serially described over the course of and following an individualized opioid taper. In addition, functional improvements and subject-level predictors of response will be described.
Study details
- Official title
- Effect of Opioid Taper on Pain Responses in Patients With Chronic Pain
- Conditions
- Interventions
- Other: Opioid Taper Pain perception
- Sponsor
- University of Pennsylvania
- Collaborators
- National Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)
- Start date
- 2019-04-15
- Primary completion
- 2021-05-31
- Sex
- All
- Age range
- from 21 Years to 70 Years
- Healthy volunteers
- true
- Results posted
- Yes, on ClinicalTrials.gov
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. between ages of 21-70; 2. documented chronic neuropathic non-malignant pain condition of at least one year duration; 3. on \>100mg/day MED for at least 6 months; 4. have fully engaged in all prescribed non-opioid pain management treatments; 5. willing to undergo prescribed opioid taper; 6. otherwise in good physical and mental health, or in the care of a physician who is willing to take responsibility for such treatment; 7. able to understand the purpose and instructions of the study, and provide informed consent as approved by the University of Pennsylvania IRB. Exclusion Criteria: 1. meet diagnostic criteria for an active substance use disorder other than nicotine; 2. be acutely psychotic, severely depressed, and/or in need of inpatient psychiatric treatment, 3. have a neurological or psychiatric illness that would affect pain responses, including anxiety disorders; 4. have a history of heart disease, stroke, or a pacemaker or uncontrolled high blood pressure. Good cardiovascular health is stipulated to ensure subjects can tolerate the sympathetic nervous system responses associated with the pain induction procedures.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT03912298